The Quietude Study: Quetiapine Use for Agitated Depression:Seroquel vs.Lexapro: Canada

The Quietude Study: Quetiapine Use for Agitated Depression
This study is currently recruiting participants.

Verified on May 2011 by Physicians Research And Education Network


First Received on May 20, 2011. Last Updated on May 27, 2011 History of Changes

Sponsor: Physicians Research And Education Network

Information provided by: Physicians Research And Education Network

ClinicalTrials.gov Identifier: NCT01363310

Purpose

Most individuals with major depressive disorder manifest clinically significant agitation. Concurrent agitation in a depressed individual is associated with an intensification of mood symptoms, decreased probability of recovery, increased recurrence risk, suicidality, and increased medical-service utilization. The occurrence of anxiety/agitation phenomenology in the depressed patient often invites the need for augmentation strategies (e.g. atypical antipsychotics, benzodiazepines, etc.) and complicated polypharmacy regimens. Moreover, individuals with major depressive disorder often report worsening of symptom severity, irritability, hostility, dysphoria, and significant subjective distress (This response pattern is similar to individuals with bipolar disorder).

Results from large research studies provide evidence indicating that quetiapine is capable of offering clinically significant multidimensional symptom relief in bipolar depression. Moreover, results from several trials in major depressive disorder and generalized anxiety disorder have established the efficacy of quetiapine therapy for unipolar depression and anxiety syndromes. So far, no atypical antipsychotic agent has been evaluated specifically for the treatment of agitated depression.

In this study, it is hypothesized that persons with major depressive disorder and prominent agitation (i.e. agitated depression) will exhibit a more favourable response and tolerability profile to quetiapine XR when compared to escitalopram.


Sponsors and Collaborators

Physicians Research And Education Network

Investigators

Study Director: Roger McIntyre, MD, FRCPC Physicians Research And Education Network

----

"Roger S. McIntyre, MD, FRCPC

Associate Professor of Psychiatry and Pharmacology
University of Toronto

Head of the Mood Disorders Psychopharmacology Unit
University Health Network

Toronto, Canada

Roger S. McIntyre, MD, FRCPC, is Associate Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre completed his medical degree at Dalhousie University in Halifax, Nova Scotia. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto."


Dr. McIntyre has served as a consultant for AstraZeneca, Biovail, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Organon, Pfizer, Shire, Solvay, and Wyeth. He has served on speakers bureaus for AstraZeneca, Biovail, Eli Lilly and Company, Janssen-Ortho, and Lundbeck. Dr. McIntyre also has received grant and research funding from Eli Lilly and Company, NARSAD, and the Stanley Medical Research Institute.

--

Another research study for Seroquel with a study director/Principal investigator with a conflict of interest via paid by AstraZeneca for speaking activities and consulting.
--

Bonus link

MoodsMagazine questionnaire.

"This questionnaire was developed through consultation with Roger McIntyre, MD, FRCP(C), Head, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto

Please check all items that apply to you throughout this questionnaire. The results of this self-test are only meaningful if you are honest with yourself. The following questions/answers are not tracked and cannot be saved--all information is automatically cleared as soon as you leave the page.

This questionnaire is NOT meant to replace the medical expertise of a doctor or mental health professional. It is designed to assist you and a professional in determining an accurate and timely diagnosis. Upon completion, you are encouraged to print the results provided on the final summary page so that you may review it and have a record to provide to a professional for further discussion."

Meet our
Honorary Advisory Council

Ron Ellis
Paul E. Garfinkel, FRCP(C),
Sidney H. Kennedy, FRCP(C)
The Hon. Michael J. L. Kirby
Stanley Kutcher, FRCP(C) * (hey, isn't that the PAXIL 329 co-author?)
Roger S. McIntyre, FRCP(C)
Rona Maynard
Brian Mullen
Edgardo Perez, FRCP(C)
Doris Sommer-Rotenberg
Bill Wilkerson
The Hon. Michael H. Wilson